Vacc C5
Alternative Names: VACC-C 5Latest Information Update: 17 Sep 2019
Price :
$50 *
At a glance
- Originator Bionor Pharma
- Developer Bionor Holding
- Class AIDS vaccines; Peptide vaccines; Peptides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II HIV infections
Most Recent Events
- 17 Sep 2019 Vacc C5 is still in phase I/II trials for HIV infections in Norway (Bionor Pharma website, August 2019)
- 24 Feb 2014 Pharmacodynamics and adverse events data from a phase I trial in HIV infections released by Bionor Pharma
- 30 Nov 2013 Bionor Pharma completes a phase I/II trial for HIV infections in Norway (NCT01627678)